Shares of C4 Therapeutics Inc. (CCCC) have plummeted 51% from their 52-week high of $11.38, reached in March, and trade around $5. As the company prepares for an upcoming data readout next month, it may be prudent to revisit the stock.
C4 Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of small-molecule medicines based on its proprietary technology platform, TORPEDO (Target ORiented ProtEin Degrader Optimizer). Its clinical pipeline includes Cemsidomide, formerly known as CFT7455, and CFT1946.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com